✦ LIBER ✦

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

✍ Scribed by Ku, Geoffrey Y.; Haaland, Benjamin A.; de Lima Lopes, Gilberto

Book ID: 119320601
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 281 KB
Volume: 74
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2011.04.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of gefitinib as mainten

A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China

✍ Lu Yang; Zhi-jie Wang; Tong-tong An; Hua Bai; Jun Zhao; Jian-chun Duan; Ping-pin 📂 Article 📅 2010 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 283 KB

Gefitinib Compared with Systemic Chemoth

Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials

✍ F. Wang; L.D. Wang; B. Li; Z.X. Sheng 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 835 KB

Gefitinib as first-line, compassionate u

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

✍ Argiris, Athanassios; Mittal, Namrata 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Weekly docetaxel as second line chemothe

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials

✍ Emilio Bria; Federica Cuppone; Mariangela Ciccarese; Cecilia Nisticò; Francesco 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Multicenter phase II trial of gefitinib

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03

✍ D'Addario, G.; Rauch, D.; Stupp, R.; Pless, M.; Stahel, R.; Mach, N.; Jost, L.; 📂 Article 📅 2008 🏛 Oxford University Press 🌐 English ⚖ 107 KB

Phase III trial of docetaxel (D) and car

Phase III trial of docetaxel (D) and carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)

✍ Giannakakis, Th; Mavroudis, D; Papadouris, S; Kourousis, Ch; Ziras, N; Kakolyris 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 224 KB